PREOPERATIVE RADIOTHERAPY IN ESOPHAGEAL CANCER: A CASE REPORT

  • Milica S Radić Klinika za onkologiju, Klinicki centar Niš Medicinski faultet, Univerzitet u Nišu, student doktorskih studija
  • Dušan Mitić Clinic for Oncology, Clinical Center Niš, Niš, Serbia
  • Milica Ćosić Infectious Diseases Clinic, Clinical Center of Niš, Niš, Serbia
  • Nataša Simonović

Sažetak


Carcinoma of the esophagus is a relatively rare tumor and participates with total morbidity of 1.5%. Every year, around 480000 people in the world are affected, including more men than women, and about 400000 people a year have an death outcome. Most cases are registered in less developed environments, in middle and senior life. The main risk factors include smoking, excessive alcohol consumation, the deficit of certain microelements and vitamins in the diet. The main symptoms are: progredient dysphagia, dyspepsia, while pain, swelling, coughing occur in advanced stages of the disease. The diagnosis is based on a pathohistological confirmation of the disease from the biopsied material taken by the esophagogastroscopy or by the endoscopic resection material. The therapy used in the treatment of esophagus cancers is multidisciplinary. The most common is surgical, radioteraphy, and chemotherapy. Often these three basic forms of therapy are combined. In this case report, the neoadjuvant therapy consisting of chemotherapy according to the PF protocol and transcutaneous radiotherapy gave an extremely good therapeutic response, and the disease from an unresponsive state was converted into a state of radical operability.

Reference

Akiyama H. Surgery for cancer of the of oesophagus. Baltimore: Williams & Wilkins;1990:10.

Cohen DJ, Leichman L. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. J Clin Oncol 2015;33:1754-9. [CrossRef][PubMed]

Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradio-therapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-14. [CrossRef][PubMed]

Filipović S., editor. Osnovi kliničke onkologije. Niš: Medicinski fakultet Niš; 2009.

Fléjou JF. WHO Classification of digestive tumors: the fourth edition. Ann Pathol 2010;31:S27-S31. [CrossRef][PubMed]

Hong SJ, Kim TJ, Nam KB, Lee IS, Yang CH, Cho S, et al. New TNM staging system for esophageal cancer: what chest radiologist need to know. Radiographics 2014;34:1722-40. [CrossRef][PubMed]

Ishikawa H, Nonaka T, Sakurai H, Tamaki Y, Kitamoto Y, Ebara T, et al. Usefulness of intraluminal brachy-therapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results. Int J Radiat Oncol Biol Phys 2010; 76:452-9. [CrossRef][PubMed]

Leggett CL, Lewis JT, Wu TT, Schleck CD, Zinsmeister AR, Dunagan KT, et al. Clinical and histologic determinants of mortality for patients with Barrett’s esophagus-related T1 esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2015;13(4):658-64. [CrossRef][PubMed]

Mileusnić D, Durbaba M, editors. Radijaciona onko-logija. Beograd: Alta nova;2012:266-76.

National Comprehensive Cancer Network. NCCN clini-cal practice guidelines in oncology. 2008.

Shah MA. Update on metastatic gastric and esopha-geal cancers. J Clin Oncol 2015;33:1760-9. [CrossRef][PubMed]

Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM Classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell;2010.

Stahl M, Oliveira J. on behalf of the ESMO Guidelines Working Group. Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii21-ii22. [CrossRef][PubMed]

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. [CrossRef][PubMed]

Washington K, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with carcinoma of the esophagus. Arch Pathol Lab Med 2009; 133(10): 1539-51.

Ychou M, Boige V, Pignon J, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy com-pared with surgery alone for resectable gastroeso-phageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29: 1715-21. [CrossRef][PubMed]

Objavljeno
2021/01/29
Rubrika
Prikaz bolesnika